This site is intended for healthcare professionals
Psoriasis Academy

PsoMOT 2019

Read time: 505 mins
The second edition of the Almirall funded “Psoriasis Management of patients Over Time” (PsoMOT) meeting was held in Amsterdam between the 16 and 17 November 2019.

Featuring thought-provoking presentations from some of Europe’s leading psoriasis experts, the meeting offered attendees the opportunity to gain valuable insight into some of the latest innovations and biggest controversies in the field.

This year’s chairs welcome guests from around the world to the second “Psoriasis Management of patients Over Time” (PsoMOT) meeting.

Professor Diamant Thaçi and Professor Matthias Augustin introduce the scientific programme for PsoMOT 2019. 

Click on the section links for access to more footage from the event, in which the expert panel tackle a range of hot topics and offer valuable practical advice on providing the best possible standard of care to patients with psoriasis.

Professor Luigi Naldi and Dr Esteban Daudén discuss the role of real-world evidence in the development of treatments for psoriasis. What is the value of this frequently overlooked source of information and how can it be used to complement data collected in clinical trials?

Real-World Evidence Studies: Expectation vs. RealityProfessor Luigi Naldi (Italy)

Is real-world evidence better than clinical trial data? Find out what Professor Luigi Naldi has to say in the video below.

Register free for full access to

The well-documented efficacy of biologic therapies has made them an increasingly popular choice for the treatment of psoriasis since the earliest agent was approved in 2003. 

Since then, a range of different biologics targeting various cytokines involved in the development and maintenance of psoriasis have become available, but their introduction has brought new challenges. In the following videos Professor Diamant Tha, Professor Stefano Piaserico and Professor Ulrich Mrowietz reflect on what can be done to overcome these challenges and maximise the potential of these game-changing drugs.

Register free for full access to

In the “age of biologics”, is there still a place for non-biologic systemic therapies? Professor Wolf-Henning Boehncke and Dr Deepak Balak discuss the appropriate use of conventional treatments for patients with psoriasis, particularly those presenting with comorbidities, as well as information on their long-term safety and efficacy.

Managing psoriasis patients with non-biologic systemic therapies – Professor Wolf-Henning Boehncke (Switzerland)

The efficacy of biologics in the treatment of psoriasis is well-documented yet use of conventional treatments remains common in clinical practice, but why is this the case?

Register free for full access to

Severity definitions in psoriasis drive the clinical decision-making process but lack consistency across the field. Professor Peter van de Kerkhof, Professor Ulrich Mrowietz and Professor Luigi Naldi discuss the importance of establishing internationally agreed psoriasis severity definitions, and what is being done to ensure that this is achieved in the future.

Masterclass on the new International Psoriasis Council guidelines - Professor Peter van de Kerkhof (The Netherlands)

Find out how the latest consensus statement from the International Psoriasis Council (IPC) addresses the major limitations associated with current psoriasis scoring systems.

Register free for full access to

Optimisation of psoriasis treatment strategies requires careful consideration of a number of patient specific factors, from co-morbidities to what really matters to the patient. Dr Esteban Daudén and Professor Matthias delve deep into how building a comprehensive patient profile can help inform treatment decisions and ultimately lead to improved patient outcomes. Meanwhile, Professor Wolf-Henning Boehncke conducts a workshop that puts this principle into practice.

Psoriasis – it is not just about the skin – Dr Esteban Daudén (Spain)

Does early management of psoriasis and its co-morbidities improve the outcome of the disease?

Register free for full access to

If you were left wanting to find out more about any of the topics covered at PsoMOT 2019, you were not alone. Find out how the expert faculty answered the questions raised by their peers throughout the event in this series of Q&A discussions.  Meanwhile, Professor Peter van de Kerkhof and Professor Diamant Thaçi round-off proceedings with a brief summary of the meeting highlights.

Conclusions and wrap-upProfessor Peter van de Kerkhof (The Netherlands) and Professor Diamant Thaçi (Germany)

What were the take-home messages from PsoMOT 2019? Find out in this brief round-up presented by Professor Peter van de Kerkhof and Professor Diamant Thaçi.

Register free for full access to


Diamant Thaçi


Professor Diamant Thaçi graduated in 1989 from the University of Prishtina, Kosovo with a medical degree. He specialised in Dermatology and Venereology in 1995 at the Johnann Wolfgang Goethe University Department of Dermatology and Venereology in Frankfurt, Germany. From 1997—2011, Professor Thaçi held the roles of Senior Consulting Specialist in Dermatology, Director of Clinical Research and head of the photo-dermatology division. 

In 2011, he was appointed as Associate Professor of Dermatology, Venereology and Allergology at the Goethe University in Frankfurt, Germany. Since 2013, he has been a Director and full university professor at the Institute and Comprehensive Centre for Inflammation Medicine, University of Lübeck, Germany. He is also Chairman of the inflammatory board at the University Hospital Schleswig-Holstein Campus in Lübeck, Germany.  

Register free for full access to